• Home
  • |
  • Press Release
  • |
  • Global Generic Oncology Drug Market Stimulated by High Cancer Treatment Cost

Global Generic Oncology Drug Market to Reach US$ 36.9 Billion by 2027, Stimulated by High Cancer Treatment Cost

June 05, 2019

According to the latest report by IMARC Group, titled “Generic Oncology Drug Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, the global generic oncology drug market reached a value of US$ 26.1 Billion in 2021. Cancer is a lifestyle disease which is characterized by the rapid and uncontrolled growth of abnormal cells that invade nearby tissues and result in the formulation of a tumor. Over the years, cancer has emerged as one of the leading causes of mortality worldwide; however, prognosis has improved with advancements in treatment. On account of the complexity of cancer care and high cost associated with cancer treatment, various pharmaceutical companies are taking an interest in the development of generic oncology drugs. These drugs are bioequivalent of brand-name medicines that provide similar pharmacological effects, including safety, efficacy, dosage, intended use, side effect and route of administration. The availability of oncology generics can further improve cancer treatment outcomes by increasing drug adherence among patients.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Generic Oncology Market Trends:

Owing to the rising geriatric population and environmental degradation, the prevalence of cancer has increased around the world. As a result, governments in numerous countries are encouraging the adoption of generic oncology drugs as a cost-containment measure. They are also financing cancer-related research and development (R&D) activities and investing in the production of anti-cancer drugs which, in turn, is bolstering the growth of the global generic oncology drug market. Moreover, these drugs play a pivotal role in cancer treatment since some of the anti-cancer drugs are only available in the form of generics. Apart from this, generic drugs generally require low capital investments as the companies only incur the manufacturing cost without any expenditure on drug discovery, drug development, advertising and distribution of free samples. Further, several branded oncology drugs are anticipated to lose patent protection in the upcoming years, which will provide lucrative opportunities to generic oncology drug manufacturers. Looking forward, the market is projected to reach a value of US$ 36.9 Billion by 2027, exhibiting a CAGR of 5.8% during 2022-2027.

Market Summary:

  • Region-wise, the market has been classified into Europe, Asia Pacific, North America, Latin America, and Middle East and Africa. Amongst these, North America represents the leading market for oncology generics, accounting for the majority of the global share.
  • The competitive landscape of the market has been examined in the report, along with a detailed list of the major players operating in the industry.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Generic Oncology Drug Market to Reach US$ 36.9 Billion by 2027, Stimulated by High Cancer Treatment Cost
Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More